http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 04 Mar 2026 09:09:39 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Downgrades/D.+Boral+Capital+Downgrades+Tevogen+Bio+%28TVGN%29+to+Hold/26108195.html <p>D. Boral Capital analyst Jason Kolbert downgraded Tevogen Bio (NASDAQ: TVGN) from Buy to Hold.</p><p>For an analyst ratings summary and ratings history on Tevogen Bio <a href="http://www.streetinsider.com/rating_history.php?q=TVGN">click here</a>. For more ratings news on Tevogen Bio <a href="http://www.streetinsider.com/stock_lookup_news.php?q=TVGN&amp;type=analyst">click here</a>.</p><p>Shares of Tevogen Bio closed at $0.25 yesterday.</p> http://www.streetinsider.com/Downgrades/D.+Boral+Capital+Downgrades+Tevogen+Bio+%28TVGN%29+to+Hold/26108195.html Wed, 04 Mar 2026 09:09:39 -0500 TVGN http://www.streetinsider.com/SEC+Filings/Form++424B3++++++Tevogen+Bio+Holdings+++++++++++++++++/26108192.html si-local-file:///var/storage/secattach/20260304/26108192.html http://www.streetinsider.com/SEC+Filings/Form++424B3++++++Tevogen+Bio+Holdings+++++++++++++++++/26108192.html Wed, 04 Mar 2026 09:09:00 -0500 O.54782335 TVGN http://www.streetinsider.com/SEC+Filings/Form++424B3++++++Tevogen+Bio+Holdings+++++++++++++++++/26108192.html si-local-file:///var/storage/secattach/20260304/26108192.html http://www.streetinsider.com/SEC+Filings/Form++424B3++++++Tevogen+Bio+Holdings+++++++++++++++++/26108192.html Wed, 04 Mar 2026 09:09:00 -0500 O.54782335 TVGN http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Tevogen+Bio+Holdings++++++For%3A+Mar+03/26108151.html si-local-file:///var/storage/secattach/20260304/26108151.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Tevogen+Bio+Holdings++++++For%3A+Mar+03/26108151.html Wed, 04 Mar 2026 09:04:00 -0500 O.54782335 TVGN http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Tevogen+Bio+Holdings++++++For%3A+Mar+03/26108151.html si-local-file:///var/storage/secattach/20260304/26108151.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Tevogen+Bio+Holdings++++++For%3A+Mar+03/26108151.html Wed, 04 Mar 2026 09:04:00 -0500 O.54782335 TVGN http://www.streetinsider.com/Analyst+PT+Change/Tevogen+Bio+%28TVGN%29+PT+Lowered+to+%242+at+D.+Boral+Capital/26097310.html <p>D. Boral Capital analyst Jason Kolbert lowered the price target on Tevogen Bio (NASDAQ: TVGN) to $2.00 (from $5.00) while maintaining a Buy rating.</p><p>The analyst comments "We are lowering our price target as a result of multiple factors. The fall in the stock price increases the company's dilution risk. In addition, we are pushing back the timing of commercialization too. These changes combine to lower our target valuation from $5.0 to $2.0."</p> http://www.streetinsider.com/Analyst+PT+Change/Tevogen+Bio+%28TVGN%29+PT+Lowered+to+%242+at+D.+Boral+Capital/26097310.html Tue, 03 Mar 2026 08:42:52 -0500 TVGN http://www.streetinsider.com/Analyst+Comments/Tevogen+Bio+%28TVGN%29+PT+Lowered+to+%242+at+D.+Boral+Capital/26097310.html <p>D. Boral Capital analyst Jason Kolbert lowered the price target on Tevogen Bio (NASDAQ: TVGN) to $2.00 (from $5.00) while maintaining a Buy rating.</p><p>The analyst comments "We are lowering our price target as a result of multiple factors. The fall in the stock price increases the company's dilution risk. In addition, we are pushing back the timing of commercialization too. These changes combine to lower our target valuation from $5.0 to $2.0."</p> http://www.streetinsider.com/Analyst+Comments/Tevogen+Bio+%28TVGN%29+PT+Lowered+to+%242+at+D.+Boral+Capital/26097310.html Tue, 03 Mar 2026 08:42:52 -0500 TVGN http://www.streetinsider.com/Corporate+News/Tevogen+signs+letter+of+intent+to+evaluate+CRO+acquisition/26080029.html <p>Tevogen Bio Holdings Inc. (NASDAQ: TVGN) announced it has signed a non-exclusive, non-binding letter of intent to evaluate a potential acquisition of a global contract research organization.</p><p>The Warren, New Jersey-based company stated the proposed transaction could expand its clinical development capabilities and support its evolution into a revenue-generating healthcare enterprise, according to a press release.</p><p>"The potential acquisition of a CRO could introduce revenue-generating service capabilities while allowing us to optimize trial execution internally," said Dr. Ryan Saadi, founder and chief executive officer of Tevogen. "We believe this combination of operational control and service revenue may strengthen earnings visibility, support a http://www.streetinsider.com/Corporate+News/Tevogen+signs+letter+of+intent+to+evaluate+CRO+acquisition/26080029.html Fri, 27 Feb 2026 14:20:29 -0500 TVGN TVGNW http://www.streetinsider.com/Corporate+News/Tevogen+signs+letter+of+intent+to+evaluate+CRO+acquisition/26080029.html <p>Tevogen Bio Holdings Inc. (NASDAQ: TVGN) announced it has signed a non-exclusive, non-binding letter of intent to evaluate a potential acquisition of a global contract research organization.</p><p>The Warren, New Jersey-based company stated the proposed transaction could expand its clinical development capabilities and support its evolution into a revenue-generating healthcare enterprise, according to a press release.</p><p>"The potential acquisition of a CRO could introduce revenue-generating service capabilities while allowing us to optimize trial execution internally," said Dr. Ryan Saadi, founder and chief executive officer of Tevogen. "We believe this combination of operational control and service revenue may strengthen earnings visibility, support a http://www.streetinsider.com/Corporate+News/Tevogen+signs+letter+of+intent+to+evaluate+CRO+acquisition/26080029.html Fri, 27 Feb 2026 14:20:29 -0500 TVGN TVGNW http://www.streetinsider.com/Mergers+and+Acquisitions/Tevogen+signs+letter+of+intent+to+evaluate+CRO+acquisition/26080029.html <p>Tevogen Bio Holdings Inc. (NASDAQ: TVGN) announced it has signed a non-exclusive, non-binding letter of intent to evaluate a potential acquisition of a global contract research organization.</p><p>The Warren, New Jersey-based company stated the proposed transaction could expand its clinical development capabilities and support its evolution into a revenue-generating healthcare enterprise, according to a press release.</p><p>"The potential acquisition of a CRO could introduce revenue-generating service capabilities while allowing us to optimize trial execution internally," said Dr. Ryan Saadi, founder and chief executive officer of Tevogen. "We believe this combination of operational control and service revenue may strengthen earnings visibility, support a http://www.streetinsider.com/Mergers+and+Acquisitions/Tevogen+signs+letter+of+intent+to+evaluate+CRO+acquisition/26080029.html Fri, 27 Feb 2026 14:20:29 -0500 TVGN TVGNW http://www.streetinsider.com/Mergers+and+Acquisitions/Tevogen+signs+letter+of+intent+to+evaluate+CRO+acquisition/26080029.html <p>Tevogen Bio Holdings Inc. (NASDAQ: TVGN) announced it has signed a non-exclusive, non-binding letter of intent to evaluate a potential acquisition of a global contract research organization.</p><p>The Warren, New Jersey-based company stated the proposed transaction could expand its clinical development capabilities and support its evolution into a revenue-generating healthcare enterprise, according to a press release.</p><p>"The potential acquisition of a CRO could introduce revenue-generating service capabilities while allowing us to optimize trial execution internally," said Dr. Ryan Saadi, founder and chief executive officer of Tevogen. "We believe this combination of operational control and service revenue may strengthen earnings visibility, support a http://www.streetinsider.com/Mergers+and+Acquisitions/Tevogen+signs+letter+of+intent+to+evaluate+CRO+acquisition/26080029.html Fri, 27 Feb 2026 14:20:29 -0500 TVGN TVGNW http://www.streetinsider.com/Press+Releases/Tevogen+Signs+Letter+of+Intent+to+Evaluate+Potential+Acquisition+of+a+Contract+Research+Organization/26080026.html <p>WARREN, N.J., Feb. 27, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=D2ixpTtMNOiEP6JeIKXUPVLCVkjc6HPS8TM8kIkVG9YiBAtoh3Ew5VHm6TvW_LGlVQfp2vzSGs3Q9ki0V0OLxQ==" rel="nofollow" target="_blank">Tevogen</a> (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=zeWfpDfMqQXGMaOrglCjRZj2KN1utlhlGEouqo1GYIxxwm5Em9d-M7DtBVjq93YoIS1-gxgwrMHXTVcvwcEP-bzszCBUYNI3XWXlRceTrQ-AIzmLnlFKMjPNSSPd-bs0" rel="nofollow" target="_blank">TVGN</a>) today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent (“LoI”) to evaluate a potential transaction with a distinguished global Contract Research Organization (“CRO”). If consummated, the proposed transaction could expand Tevogen’s clinical development capabilities and could support the Company’s evolution into a revenue-generating healthcare enterprise.</p> <p>Dr. Ryan Saadi, Founder and Chief Executive Officer of Tevogen, stated, “The potential acquisition of a CRO could introduce revenue-generating service capabilities while allowing http://www.streetinsider.com/Press+Releases/Tevogen+Signs+Letter+of+Intent+to+Evaluate+Potential+Acquisition+of+a+Contract+Research+Organization/26080026.html Fri, 27 Feb 2026 14:20:00 -0500 A.06270839 O.34653200 O.54782335 TVGN TVGNW http://www.streetinsider.com/Press+Releases/Tevogen+Signs+Letter+of+Intent+to+Evaluate+Potential+Acquisition+of+a+Contract+Research+Organization/26080026.html <p>WARREN, N.J., Feb. 27, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=D2ixpTtMNOiEP6JeIKXUPVLCVkjc6HPS8TM8kIkVG9YiBAtoh3Ew5VHm6TvW_LGlVQfp2vzSGs3Q9ki0V0OLxQ==" rel="nofollow" target="_blank">Tevogen</a> (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=zeWfpDfMqQXGMaOrglCjRZj2KN1utlhlGEouqo1GYIxxwm5Em9d-M7DtBVjq93YoIS1-gxgwrMHXTVcvwcEP-bzszCBUYNI3XWXlRceTrQ-AIzmLnlFKMjPNSSPd-bs0" rel="nofollow" target="_blank">TVGN</a>) today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent (“LoI”) to evaluate a potential transaction with a distinguished global Contract Research Organization (“CRO”). If consummated, the proposed transaction could expand Tevogen’s clinical development capabilities and could support the Company’s evolution into a revenue-generating healthcare enterprise.</p> <p>Dr. Ryan Saadi, Founder and Chief Executive Officer of Tevogen, stated, “The potential acquisition of a CRO could introduce revenue-generating service capabilities while allowing http://www.streetinsider.com/Press+Releases/Tevogen+Signs+Letter+of+Intent+to+Evaluate+Potential+Acquisition+of+a+Contract+Research+Organization/26080026.html Fri, 27 Feb 2026 14:20:00 -0500 A.06270839 O.34653200 O.54782335 TVGN TVGNW http://www.streetinsider.com/Press+Releases/Tevogen+Signs+Letter+of+Intent+to+Evaluate+Potential+Acquisition+of+a+Contract+Research+Organization/26080026.html <p>WARREN, N.J., Feb. 27, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=D2ixpTtMNOiEP6JeIKXUPVLCVkjc6HPS8TM8kIkVG9YiBAtoh3Ew5VHm6TvW_LGlVQfp2vzSGs3Q9ki0V0OLxQ==" rel="nofollow" target="_blank">Tevogen</a> (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=zeWfpDfMqQXGMaOrglCjRZj2KN1utlhlGEouqo1GYIxxwm5Em9d-M7DtBVjq93YoIS1-gxgwrMHXTVcvwcEP-bzszCBUYNI3XWXlRceTrQ-AIzmLnlFKMjPNSSPd-bs0" rel="nofollow" target="_blank">TVGN</a>) today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent (“LoI”) to evaluate a potential transaction with a distinguished global Contract Research Organization (“CRO”). If consummated, the proposed transaction could expand Tevogen’s clinical development capabilities and could support the Company’s evolution into a revenue-generating healthcare enterprise.</p> <p>Dr. Ryan Saadi, Founder and Chief Executive Officer of Tevogen, stated, “The potential acquisition of a CRO could introduce revenue-generating service capabilities while allowing http://www.streetinsider.com/Press+Releases/Tevogen+Signs+Letter+of+Intent+to+Evaluate+Potential+Acquisition+of+a+Contract+Research+Organization/26080026.html Fri, 27 Feb 2026 14:20:00 -0500 A.06270839 O.34653200 O.54782335 TVGN TVGNW http://www.streetinsider.com/Press+Releases/Tevogen+Signs+Letter+of+Intent+to+Evaluate+Potential+Acquisition+of+a+Contract+Research+Organization/26080026.html <p>WARREN, N.J., Feb. 27, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=D2ixpTtMNOiEP6JeIKXUPVLCVkjc6HPS8TM8kIkVG9YiBAtoh3Ew5VHm6TvW_LGlVQfp2vzSGs3Q9ki0V0OLxQ==" rel="nofollow" target="_blank">Tevogen</a> (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=zeWfpDfMqQXGMaOrglCjRZj2KN1utlhlGEouqo1GYIxxwm5Em9d-M7DtBVjq93YoIS1-gxgwrMHXTVcvwcEP-bzszCBUYNI3XWXlRceTrQ-AIzmLnlFKMjPNSSPd-bs0" rel="nofollow" target="_blank">TVGN</a>) today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent (“LoI”) to evaluate a potential transaction with a distinguished global Contract Research Organization (“CRO”). If consummated, the proposed transaction could expand Tevogen’s clinical development capabilities and could support the Company’s evolution into a revenue-generating healthcare enterprise.</p> <p>Dr. Ryan Saadi, Founder and Chief Executive Officer of Tevogen, stated, “The potential acquisition of a CRO could introduce revenue-generating service capabilities while allowing http://www.streetinsider.com/Press+Releases/Tevogen+Signs+Letter+of+Intent+to+Evaluate+Potential+Acquisition+of+a+Contract+Research+Organization/26080026.html Fri, 27 Feb 2026 14:20:00 -0500 A.06270839 O.34653200 O.54782335 TVGN TVGNW http://www.streetinsider.com/Press+Releases/Tevogen+Signs+Letter+of+Intent+to+Evaluate+Potential+Acquisition+of+a+Contract+Research+Organization/26080026.html <p>WARREN, N.J., Feb. 27, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=D2ixpTtMNOiEP6JeIKXUPVLCVkjc6HPS8TM8kIkVG9YiBAtoh3Ew5VHm6TvW_LGlVQfp2vzSGs3Q9ki0V0OLxQ==" rel="nofollow" target="_blank">Tevogen</a> (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=zeWfpDfMqQXGMaOrglCjRZj2KN1utlhlGEouqo1GYIxxwm5Em9d-M7DtBVjq93YoIS1-gxgwrMHXTVcvwcEP-bzszCBUYNI3XWXlRceTrQ-AIzmLnlFKMjPNSSPd-bs0" rel="nofollow" target="_blank">TVGN</a>) today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent (“LoI”) to evaluate a potential transaction with a distinguished global Contract Research Organization (“CRO”). If consummated, the proposed transaction could expand Tevogen’s clinical development capabilities and could support the Company’s evolution into a revenue-generating healthcare enterprise.</p> <p>Dr. Ryan Saadi, Founder and Chief Executive Officer of Tevogen, stated, “The potential acquisition of a CRO could introduce revenue-generating service capabilities while allowing http://www.streetinsider.com/Press+Releases/Tevogen+Signs+Letter+of+Intent+to+Evaluate+Potential+Acquisition+of+a+Contract+Research+Organization/26080026.html Fri, 27 Feb 2026 14:20:00 -0500 A.06270839 O.34653200 O.54782335 TVGN TVGNW http://www.streetinsider.com/Globe+Newswire/Tevogen+Signs+Letter+of+Intent+to+Evaluate+Potential+Acquisition+of+a+Contract+Research+Organization/26080026.html <p>WARREN, N.J., Feb. 27, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=D2ixpTtMNOiEP6JeIKXUPVLCVkjc6HPS8TM8kIkVG9YiBAtoh3Ew5VHm6TvW_LGlVQfp2vzSGs3Q9ki0V0OLxQ==" rel="nofollow" target="_blank">Tevogen</a> (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=zeWfpDfMqQXGMaOrglCjRZj2KN1utlhlGEouqo1GYIxxwm5Em9d-M7DtBVjq93YoIS1-gxgwrMHXTVcvwcEP-bzszCBUYNI3XWXlRceTrQ-AIzmLnlFKMjPNSSPd-bs0" rel="nofollow" target="_blank">TVGN</a>) today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent (“LoI”) to evaluate a potential transaction with a distinguished global Contract Research Organization (“CRO”). If consummated, the proposed transaction could expand Tevogen’s clinical development capabilities and could support the Company’s evolution into a revenue-generating healthcare enterprise.</p> <p>Dr. Ryan Saadi, Founder and Chief Executive Officer of Tevogen, stated, “The potential acquisition of a CRO could introduce revenue-generating service capabilities while allowing http://www.streetinsider.com/Globe+Newswire/Tevogen+Signs+Letter+of+Intent+to+Evaluate+Potential+Acquisition+of+a+Contract+Research+Organization/26080026.html Fri, 27 Feb 2026 14:20:00 -0500 A.06270839 O.34653200 O.54782335 TVGN TVGNW http://www.streetinsider.com/Globe+Newswire/Tevogen+Signs+Letter+of+Intent+to+Evaluate+Potential+Acquisition+of+a+Contract+Research+Organization/26080026.html <p>WARREN, N.J., Feb. 27, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=D2ixpTtMNOiEP6JeIKXUPVLCVkjc6HPS8TM8kIkVG9YiBAtoh3Ew5VHm6TvW_LGlVQfp2vzSGs3Q9ki0V0OLxQ==" rel="nofollow" target="_blank">Tevogen</a> (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=zeWfpDfMqQXGMaOrglCjRZj2KN1utlhlGEouqo1GYIxxwm5Em9d-M7DtBVjq93YoIS1-gxgwrMHXTVcvwcEP-bzszCBUYNI3XWXlRceTrQ-AIzmLnlFKMjPNSSPd-bs0" rel="nofollow" target="_blank">TVGN</a>) today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent (“LoI”) to evaluate a potential transaction with a distinguished global Contract Research Organization (“CRO”). If consummated, the proposed transaction could expand Tevogen’s clinical development capabilities and could support the Company’s evolution into a revenue-generating healthcare enterprise.</p> <p>Dr. Ryan Saadi, Founder and Chief Executive Officer of Tevogen, stated, “The potential acquisition of a CRO could introduce revenue-generating service capabilities while allowing http://www.streetinsider.com/Globe+Newswire/Tevogen+Signs+Letter+of+Intent+to+Evaluate+Potential+Acquisition+of+a+Contract+Research+Organization/26080026.html Fri, 27 Feb 2026 14:20:00 -0500 A.06270839 O.34653200 O.54782335 TVGN TVGNW http://www.streetinsider.com/Globe+Newswire/Tevogen+Signs+Letter+of+Intent+to+Evaluate+Potential+Acquisition+of+a+Contract+Research+Organization/26080026.html <p>WARREN, N.J., Feb. 27, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=D2ixpTtMNOiEP6JeIKXUPVLCVkjc6HPS8TM8kIkVG9YiBAtoh3Ew5VHm6TvW_LGlVQfp2vzSGs3Q9ki0V0OLxQ==" rel="nofollow" target="_blank">Tevogen</a> (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=zeWfpDfMqQXGMaOrglCjRZj2KN1utlhlGEouqo1GYIxxwm5Em9d-M7DtBVjq93YoIS1-gxgwrMHXTVcvwcEP-bzszCBUYNI3XWXlRceTrQ-AIzmLnlFKMjPNSSPd-bs0" rel="nofollow" target="_blank">TVGN</a>) today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent (“LoI”) to evaluate a potential transaction with a distinguished global Contract Research Organization (“CRO”). If consummated, the proposed transaction could expand Tevogen’s clinical development capabilities and could support the Company’s evolution into a revenue-generating healthcare enterprise.</p> <p>Dr. Ryan Saadi, Founder and Chief Executive Officer of Tevogen, stated, “The potential acquisition of a CRO could introduce revenue-generating service capabilities while allowing http://www.streetinsider.com/Globe+Newswire/Tevogen+Signs+Letter+of+Intent+to+Evaluate+Potential+Acquisition+of+a+Contract+Research+Organization/26080026.html Fri, 27 Feb 2026 14:20:00 -0500 A.06270839 O.34653200 O.54782335 TVGN TVGNW http://www.streetinsider.com/Globe+Newswire/Tevogen+Signs+Letter+of+Intent+to+Evaluate+Potential+Acquisition+of+a+Contract+Research+Organization/26080026.html <p>WARREN, N.J., Feb. 27, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=D2ixpTtMNOiEP6JeIKXUPVLCVkjc6HPS8TM8kIkVG9YiBAtoh3Ew5VHm6TvW_LGlVQfp2vzSGs3Q9ki0V0OLxQ==" rel="nofollow" target="_blank">Tevogen</a> (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=zeWfpDfMqQXGMaOrglCjRZj2KN1utlhlGEouqo1GYIxxwm5Em9d-M7DtBVjq93YoIS1-gxgwrMHXTVcvwcEP-bzszCBUYNI3XWXlRceTrQ-AIzmLnlFKMjPNSSPd-bs0" rel="nofollow" target="_blank">TVGN</a>) today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent (“LoI”) to evaluate a potential transaction with a distinguished global Contract Research Organization (“CRO”). If consummated, the proposed transaction could expand Tevogen’s clinical development capabilities and could support the Company’s evolution into a revenue-generating healthcare enterprise.</p> <p>Dr. Ryan Saadi, Founder and Chief Executive Officer of Tevogen, stated, “The potential acquisition of a CRO could introduce revenue-generating service capabilities while allowing http://www.streetinsider.com/Globe+Newswire/Tevogen+Signs+Letter+of+Intent+to+Evaluate+Potential+Acquisition+of+a+Contract+Research+Organization/26080026.html Fri, 27 Feb 2026 14:20:00 -0500 A.06270839 O.34653200 O.54782335 TVGN TVGNW http://www.streetinsider.com/Globe+Newswire/Tevogen+Signs+Letter+of+Intent+to+Evaluate+Potential+Acquisition+of+a+Contract+Research+Organization/26080026.html <p>WARREN, N.J., Feb. 27, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=D2ixpTtMNOiEP6JeIKXUPVLCVkjc6HPS8TM8kIkVG9YiBAtoh3Ew5VHm6TvW_LGlVQfp2vzSGs3Q9ki0V0OLxQ==" rel="nofollow" target="_blank">Tevogen</a> (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=zeWfpDfMqQXGMaOrglCjRZj2KN1utlhlGEouqo1GYIxxwm5Em9d-M7DtBVjq93YoIS1-gxgwrMHXTVcvwcEP-bzszCBUYNI3XWXlRceTrQ-AIzmLnlFKMjPNSSPd-bs0" rel="nofollow" target="_blank">TVGN</a>) today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent (“LoI”) to evaluate a potential transaction with a distinguished global Contract Research Organization (“CRO”). If consummated, the proposed transaction could expand Tevogen’s clinical development capabilities and could support the Company’s evolution into a revenue-generating healthcare enterprise.</p> <p>Dr. Ryan Saadi, Founder and Chief Executive Officer of Tevogen, stated, “The potential acquisition of a CRO could introduce revenue-generating service capabilities while allowing http://www.streetinsider.com/Globe+Newswire/Tevogen+Signs+Letter+of+Intent+to+Evaluate+Potential+Acquisition+of+a+Contract+Research+Organization/26080026.html Fri, 27 Feb 2026 14:20:00 -0500 A.06270839 O.34653200 O.54782335 TVGN TVGNW http://www.streetinsider.com/SEC+Filings/Form++424B3++++++Tevogen+Bio+Holdings+++++++++++++++++/26066028.html si-local-file:///var/storage/secattach/20260226/26066028.html http://www.streetinsider.com/SEC+Filings/Form++424B3++++++Tevogen+Bio+Holdings+++++++++++++++++/26066028.html Thu, 26 Feb 2026 09:36:00 -0500 O.54782335 TVGN http://www.streetinsider.com/SEC+Filings/Form++424B3++++++Tevogen+Bio+Holdings+++++++++++++++++/26066028.html si-local-file:///var/storage/secattach/20260226/26066028.html http://www.streetinsider.com/SEC+Filings/Form++424B3++++++Tevogen+Bio+Holdings+++++++++++++++++/26066028.html Thu, 26 Feb 2026 09:36:00 -0500 O.54782335 TVGN http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Tevogen+Bio+Holdings++++++For%3A+Feb+19/26061402.html si-local-file:///var/storage/secattach/20260225/26061402.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Tevogen+Bio+Holdings++++++For%3A+Feb+19/26061402.html Wed, 25 Feb 2026 17:01:00 -0500 O.54782335 TVGN http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Tevogen+Bio+Holdings++++++For%3A+Feb+19/26061402.html si-local-file:///var/storage/secattach/20260225/26061402.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Tevogen+Bio+Holdings++++++For%3A+Feb+19/26061402.html Wed, 25 Feb 2026 17:01:00 -0500 O.54782335 TVGN